683 Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

683 Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-76,116	Closed	-$413K	–	167
2024 Q4	$413K	Buy	+76,116	New	+$359K	0.03%	161

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

683 Capital Management's DMAC Position: Q1 2025 in Review

683 Capital Management sold out of DiaMedica Therapeutics (DMAC) in Q1 2025, closing a stake of 76,116 shares — an estimated $413K sold.

683 Capital Management first reported a position in DMAC in Q4 2024 and held it in 1 quarter. The position peaked at $413K in Q4 2024. 57 funds tracked by Wall St. Rank hold DMAC as of Q1 2025.

683 Capital Management reported no remaining DiaMedica Therapeutics position as of Q1 2025 after selling out during the quarter.
683 Capital Management sold 76,116 DiaMedica Therapeutics shares in Q1 2025, an estimated $413K.
683 Capital Management first reported a position in DiaMedica Therapeutics in Q4 2024 and held it in 1 quarter.
683 Capital Management's DiaMedica Therapeutics position peaked at $413K in Q4 2024.
57 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.